“Clinically-validated and minimally-invasive treatment options for patients with both coronary artery disease and diabetes has represented a significant unmet clinical need for the diabetes community for quite some time,” said Dr. Scott W. Lee, M.D., clinical professor of medicine at Loma Linda University Medical Center near Los Angeles and medical director of global clinical research for Medtronic Diabetes in Northridge, Calif., who will present the results of the diabetes analysis. “Considering the challenges that are presented when treating diabetes patients with CAD, physicians can have confidence in the consistently low event rates in both patients with and without diabetes when using this device.”The analysis will also feature additional outcomes for important safety measures, comparing insulin-dependent- and non-insulin-dependent diabetes patients to patients without diabetes. Rates are similar among non-insulin-dependent diabetes patients and patients without diabetes.
|RESOLUTE Pooled Diabetes Analysis: Two-Year Outcomes|
|Insulin-Dependent||Non-Insulin Dependent||Patients Without|
|Endpoint*||Diabetes Patients||Diabetes Patients||Diabetes|
|* Endpoint Key|
|• TLR = target lesion revascularization (a repeat procedure to treat the same arterial segment)|
|• CD/TVMI = cardiac death/target vessel myocardial infarction|
|• Def/Prob ST = definite/probable stent thrombosis as defined by the Academic Research Consortium (ARC)|